Doxycycline for Stabilization of Abdominal Aortic Aneurysms
| Autor: | Martin N. J. M. Wasser, Jaap F. Hamming, C.A. Meijer, van Bockel Jh, Jan H.N. Lindeman, Theo Stijnen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Aortic Rupture Anti-Inflammatory Agents Matrix Metalloproteinase Inhibitors Placebo law.invention Aortic aneurysm Aneurysm Double-Blind Method Randomized controlled trial law Internal Medicine medicine Humans Elective surgery Aged Ultrasonography Doxycycline business.industry General Medicine Middle Aged medicine.disease Abdominal aortic aneurysm Surgery Treatment Outcome Disease Progression Female business Aortic Aneurysm Abdominal Follow-Up Studies medicine.drug Abdominal surgery |
| Zdroj: | Annals of Internal Medicine. 159:815 |
| ISSN: | 0003-4819 |
| DOI: | 10.7326/0003-4819-159-12-201312170-00007 |
| Popis: | Background Doxycycline inhibits formation and progression of abdominal aortic aneurysms (AAAs) in preclinical models of the disease, but it is unclear whether and how this observation translates to humans. Objective To test whether doxycycline inhibits AAA progression in humans. Design Randomized, placebo-controlled, double-blind trial. (Dutch Trial Registry: NTR 1345) SETTING: 14 Dutch hospitals. Patients 286 patients with small AAAs between October 2008 and June 2011. Intervention Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months. Measurements The primary outcome measure was aneurysm growth at 18 months, as estimated by repeated single-observer ultrasonography. Secondary outcomes included growth at 6 and 12 months and the need for elective surgery. Results Mean aneurysm diameter (approximately 43 mm) and other baseline characteristics were similar in both groups. Doxycycline treatment was associated with increased aneurysm growth (4.1 mm in the doxycycline group vs. 3.3 mm in the placebo group at 18 months; difference, 0.8 mm [95% CI, 0.1 to 1.4 mm]; P = 0.016 mm). Twenty-one patients receiving doxycycline and 22 patients receiving placebo had elective surgical repair (Kaplan–Meier estimates were 16.1% for those receiving doxycycline and 16.5% for those receiving placebo; difference, -0.4% [CI, -9.3% to 8.5%]; P = 0.83). Time to repair was similar in the groups (P = 0.92). Limitations This study focuses on patients with small AAAs. As such, whether the data can be extrapolated to larger AAAs (>55 mm) is unclear. The high number of elective repairs (n = 43) was unanticipated. Moreover, the study did not follow patients who withdrew because of an adverse effect. Conclusion This trial found that 18 months of doxycycline therapy did not reduce aneurysm growth and did not influence the need for AAA repair or time to repair. Primary funding source The Netherlands Organisation for Health Research and Development, and the NutsOhra Fund. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|